文献速递胸部肿瘤支持与姑息治疗

VeriStrat检测在不宜一线铂类化疗的晚期非小细胞肺癌中的临床作用

The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
PubMed 文献 · Eur J Cancer · 2019-09-06

结果显示VeriStrat与生存强相关,但不是厄洛替尼疗效的预测标志物,可作为独立预后指标。

要点

  • VeriStrat是晚期NSCLC不宜铂类化疗患者的独立预后标志物。
  • VeriStrat状态不能预测厄洛替尼一线治疗的生存获益。
  • VSG患者可考虑入选临床试验,VSP患者可继续保守治疗或低毒试验。

核心结论

  • VeriStrat不是厄洛替尼一线治疗不宜铂类化疗NSCLC患者的生存预测标志物。
  • VeriStrat是独立的生存预后标志物,可与其它患者因素结合细化预后评估。

研究设计与样本

  • 随机双盲试验,纳入未治疗晚期NSCLC且因PS差或多合并症不宜铂类化疗的患者。
  • 所有患者接受积极支持治疗(ASC),并随机接受口服厄洛替尼或安慰剂每日治疗。

主要发现

  • 仅ASC管理患者中,VSG vs VSP的校正HR为0.54(p<0.001)。
  • ECOG 0-1和2-3亚组HR分别为0.25(p=0.004)和0.56(p<0.001)。
  • 年龄≥75岁亚组HR=0.49(p<0.001),IV期亚组HR=0.59(p=0.007)。
  • ECOG 2-3患者中,VSG接受ASC的2年生存率为8%,VSP为0%。

临床怎么用

  • VeriStrat可作为客观检测,结合其他患者因素用于该群体更精细的预后评估。
  • VSG患者因生存较好可考虑入选治疗试验。
  • VSP患者可继续保守治疗或参加低毒性药物试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We previously demonstrated that the median survival of patients with poor prognosis non-small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was <4 months. We evaluated whether VeriStrat could be used as a prognostic or predictive biomarker in this population. EXPERIMENTAL DESIGN: We conducted a randomised double-blind trial among patients with untreated advanced NSCLC considered unfit for platinum chemotherapy because of poor performance status (PS) or multiple comorbidities. All patients received active supportive care (ASC) and were treated with either oral erlotinib or placebo daily. Five hundred twenty-seven patients had plasma samples for VeriStrat classification: good (VeriStrat Good [VSG]) or poor (VeriStrat Poor [VSP]). Main end-point was overall survival. RESULTS: Fifty-five percent patients had VSG, and 83% had Eastern Cooperative Oncology Group (ECOG) 2-3 at baseline. VeriStrat was strongly associated with survival. Among patients managed with ASC only, the adjusted hazard ratio (HR) was 0.54 (p < 0.001) for VSG versus VSP. The association was consistent across patient factors: HR = 0.25 (p = 0.004) and HR = 0.56 (p < 0.001) for ECOG 0-1 and 2-3, respectively, HR = 0.49 (0070 < 0.001) for age≥75 years and HR = 0.59 (p = 0.007) for stage IV. Several ECOG 2-3 patients had long survival: 2-year survival was 8% for VSG patients who had ASC, compared with 0% for VSP. VeriStrat status did not predict benefit from erlotinib treatment because the HRs for erlotinib versus placebo were similar between VSG and VSP patients. CONCLUSIONS: VeriStrat was not a predictive marker for survival when considering first-line erlotinib for patients with NSCLC who had poor PS and were not recommended for platinum doublet therapies. However, VeriStrat was an independent prognostic marker of survival. It represents an objective measurement that could be considered alongside other patient factors to provide a more refined assessment of prognosis for this particular patient group. VSG patients could be selected for treatment trials because of better survival, while VSP patients can continue to be treated conservatively or offered trials of less toxic agents. TRIAL REGISTRATION ISRCTN NUMBER: ISRCTN02370070.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee SM, Upadhyay S, Lewanski C, et al. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy. Eur J Cancer. 2019. PMID: 31499384. doi:10.1016/j.ejca.2019.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。